BioVaxys Technology Corp.
BIOV.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.62M
Close$
$0.01
89.6% downside
Current Fair Value
89.6% downsideOvervalued by 89.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.62 Million |
|---|---|
| Enterprise Value | $2.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.2 |
| Beta | 1.09 |
| Outstanding Shares | 29,152,000 |
Return
| Return on Equity | 165.91% |
|---|---|
| Return on Assets | -435.65% |
| Return on Invested Capital | 133.31% |
Valuation & Multiples
| P/E Ratio | -0.91 |
|---|---|
| PEG | 3.89 |
| Price to Sales | - |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.57 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -0.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioVaxys Technology Corp.
3 employees
CEO: James Christopher Passin BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features...